Figure Detection of exon-7 CYPlAl polymorphism by PCR. The presence of the CYPl Al exon 7 mutation was investigated by PCR and restriction enzyme digestion with Ncol, essentially as described by Sheilds et al, 1993 . The polymerase chain reaction was used to amplify 195-base A point mutation in exon 7 of the human CYPIAJ gene has been described which results in an isoleucine to valine substitution (Hayashi et al, 1991) and leads to an enhancement of CYPIAl enzyme activity (Crofts et al, 1994) ; this can lead to a more efficient activation of anti-cancer drugs (LeBlanc and Waxman, 1989 ). This phenotype is present in the drug-sensitive MCF-7 WT breast cancer cells (Figure) . The MCF-7 Adr multidrug-resistant cells, however, possess the non-mutated CYPIAl genotype (Figure 1 ). This may explain the observed CYP1 Al inducibility of the MCF-7 WT cells, which is absent in the MCF-7 Adr cell line (Ivy et al, 1988 ). As discussed above, deficient (inducibility of) CYPIAI enzyme activity could lead to failure in activation of anti-cancer drugs and thus contribute to drug resistance.
In conclusion, it may be of importance to investigate a possible relationship between the mutation in exon 7 of the CYPIAl gene (which is present in about 17% of Dutch Caucasians) and clinical sensitivity to particular (regimens of) anti-cancer drugs. The rapid polymerase chain reaction method for detection of this polymorphism, as applied above, could then be of value in selecting patients for chemotherapy. 
